NCT06090266: A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 168 planned
- Started
- 24 Oct 2023
- Primary completion
- 1 Aug 2026
- Arms
- OR502 monotherapy and combination therapy dose-escalation phase (Part A), OR502 monotherapy and combination therapy dose-expansion phase (Part B)
- Results
- None posted
- 19 Oct 2023: Trial registered
- 24 Oct 2023: Trial started